Tag: Kuvan

According to the FDA, Kuvan (sapropterin dihydrochloride) was approved in 2007 as a treatment for certain types of Phenylketonuria (PKU). So, is KUVAN an enzyme replacement therapy? The answer requires a closer look at its unique pharmacological function as a cofactor, not an enzyme replacement.

In clinical trials, common adverse reactions (≥4%) in patients taking Kuvan included headache, runny nose, and sore throat. Understanding **what are the side effects of Kuvan?** is crucial for patients managing Phenylketonuria (PKU).

Approved by the FDA in 2007, Kuvan (sapropterin dihydrochloride) is a prescription medication used to address the genetic disorder phenylketonuria (PKU). This treatment specifically targets patients with BH4-responsive PKU, lowering their blood phenylalanine levels in conjunction with a restricted diet.